% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Nov 7, 2007 9:16 AM Flag

    Here's the Problem...

    I agree - if they can find a way to hang on long enough to generate solid combo data for TH-302, it will be a huge win for the shareholders. One angle on "the pickle" that I didn't note was that any potential partner on Glufo would have to look at TH-302 as a potential competing agent - the animal data on TH-302 is significantly better than Glufo and is targeted for the same solid tumor applications. So, they will either have to partner them both under the same agreement, or give the Glufo partner some kind of option on TH-302? In any case, I hope they find a way to make it work - the data does look awfully dramatic and the concept (of attacking cancer in combination from a number of different angles) seems to be the future.

    PS - My sense is 2DG is being put on the back burner, while they focus on TH-302. They didn't even mention it in the conference, and they don't have the resources to do clinical trials in more than one agent.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 2DG: I thought they said they would announce P1 results by Dec 31st.

      I agree, though, TH-302 is the most dramatic compound I have ever seen. Third parties have said the mice were cured. Cured!

      If ALL of Threshold's compounds are worth annual sales of $300 million, they can go 50/50 as far as I'm concerned: $150 x 2 (times revenue) = market cap of $300 mil, or $10/share!!!

0.8561-0.1139(-11.74%)Aug 24 4:00 PMEDT